Skip to content
University of Colorado DenverCU DenverUniversity of Colorado Anschutz Medical CampusCU Anschutz
  • Webmail
  • UCD Access
  • Canvas
  • Quick Links
 
 

Tools & Resources

  • Campus Directory
  • A-Z Index
  • Human Resources
  • University Policies
  • Auraria Library
  • Strauss Health Sciences Library

Schools & Colleges

CU Denver

  • College of Architecture and Planning
  • College of Arts & Media
  • Business School
  • School of Education & Human Development
  • College of Engineering, Design and Computing
  • College of Liberal Arts and Sciences
  • School of Public Affairs

CU Anschutz Medical Campus

  • School of Dental Medicine
  • Graduate School
  • School of Medicine
  • College of Nursing
  • Skaggs School of Pharmacy and Pharmaceutical Sciences
  • Colorado School of Public Health

CU Campuses

  • CU Anschutz Medical Campus
  • CU Boulder
  • CU Colorado Springs
  • CU Denver
  • CU Online
  • CU System

SPARK | REACH Colorado

  • Home
  • SPARK Awards
    • What We Fund
    • Application Process
    • Our Funding Sources
    • FAQs
    • Submit an Application
  • Who We Are
    • SPARK Fellows
    • External Review Board
    • SPARK Team
  • Events
    • SPARK Upcoming Events
    • SPARK Past Events
  • Get Involved
  • Resources
    • SPARK Documents
    • Applicant Support: Bootcamp Sessions
  • Contact Us
University Quick Links

Meet our SPARK Fellows

borges_500

Virginia Borges, MD

Email Address:VIRGINIA.BORGES@CUANSCHUTZ.EDU

  • Bio

Diagnostic and Therapy for Breast Cancer

This project aims to address the unmet need for effective targeted therapies in endocrine therapy-resistant, recurrent, estrogen receptor-positive (ER+) breast cancers and triple-negative breast cancers. The researchers plan to develop and test a novel diagnostic and companion therapy for semaphorin 7a (SEMA7A) expression, which has been identified as upregulated in a significant percentage of breast cancer patients and a potent driver of metastasis in preclinical models. They will validate the diagnostic in a large cohort and explore the feasibility and efficacy of a monoclonal antibody-based therapy targeting SEMA7A. The goal is to develop and test the antibody-based diagnostic and therapy, potentially leading to clinical trials to determine whether SEMA7A can predict treatment outcomes in breast cancer patients, particularly in a high-risk subset of young ER+ postpartum patients. The research team's expertise in various areas, including basic science, monoclonal antibody development, pre-clinical testing, and clinical trials, positions them to advance this innovative approach towards improving breast cancer treatment and patient outcomes. Collaborators: Traci Lyons, PhD, Alan Elder, MS, Robert Hodges, PhD, Steve Anderson, PhD and Richard Duke, PhD

Learn more about Dr. Borges

CU Innovations

CU Anschutz

Anschutz Health Sciences Building

1890 N Revere Ct

Suite 6202

Mail Stop F411

Aurora, CO 80045


303-724-6653

Facebook Twitter LinkedIn
Additional Resources
  • CU Innovations
  • SPARK@Stanford
  • Other Funding Opportunities
  • Startup Toolbox
  • Contact Us
  • Website Feedback
  • CU System
  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Accreditation
  • Employment
  • Give Now
 

© 2023 The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.

CMS Login

Webmail

UCD Access

Canvas

Opens in a new window Opens document in a new window